CysLT1R Antagonists Inhibit Tumor Growth in a Xenograft Model of Colon Cancer

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Savari, Sayeh ^a   Liu, Minghui ^a   Zhang, Yuan ^a   Sime, Wondossen ^a   Sjölander, Anita ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYSTEINYL LEUKOTRIENE 1 RECEPTOR; CYSTEINYL LEUKOTRIENE 1 RECEPTOR ANTAGONIST; CYTOKERATIN 18; G PROTEIN COUPLED RECEPTOR; KI 67 ANTIGEN; MONTELUKAST; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; ZM 198615;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; COLON CARCINOGENESIS; COLONY FORMATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; FEMALE; HCT116 CELLS; HUMANS; LEUKOTRIENE ANTAGONISTS; MICE; MICE, NUDE; RECEPTORS, LEUKOTRIENE;

EID: 84883497508     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073466     Document Type: Article

References (51)

1. Wang D, Dubois RN, (2010) Eicosanoids and cancer. Nat Rev Cancer 10: 181-193.
2. Cathcart MC, Lysaght J, Pidgeon GP, (2011) Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. Cancer Metastasis Rev 30: 363-385.
3. Fabre JE, Goulet JL, Riche E, Nguyen M, Coggins K, et al. (2002) Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J Clin Invest 109: 1373-1380.
4. Chan CC, McKee K, Tagari P, Chee P, Ford-Hutchinson A, (1990) Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Eur J Pharmacol 191: 273-280.
5. Barnes NC, Piper PJ, Costello JF, (1984) Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. Thorax 39: 500-504.
6. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, et al. (1980) Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A 77: 4354-4358.
7. Marom Z, Shelhamer JH, Bach MK, Morton DR, Kaliner M, (1982) Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 126: 449-451.
8. Nicosia S, Capra V, Rovati GE, (2001) Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 14: 3-19.
9. Fauler J, Thon A, Tsikas D, von der Hardt H, Frolich JC, (1994) Enhanced synthesis of cysteinyl leukotrienes in juvenile rheumatoid arthritis. Arthritis Rheum 37: 93-97.
10. Stenson WF (1990) Role of eicosanoids as mediators of inflammation in inflammatory bowel disease. Scand J Gastroenterol Suppl 172: 13-18.
11. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
12. Bernstein CN, Blanchard JF, Kliewer E, Wajda A, (2001) Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862.
13. Hammerbeck DM, Brown DR, (1996) Presence of immunocytes and sulfidopeptide leukotrienes in the inflamed guinea pig distal colon. Inflammation 20: 413-425.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
15. Ekbom A, Helmick C, Zack M, Adami HO, (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233.
16. Ohd JF, Nielsen CK, Campbell J, Landberg G, Lofberg H, et al. (2003) Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124: 57-70.
17. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 55: 195-227.
18. Lynch KR, O′Neill GP, Liu Q, Im DS, Sawyer N, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793.
19. Heise CE, O′Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275: 30531-30536.
20. Krell RD, Giles RE, Yee YK, Snyder DW, (1987) In vivo pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 243: 557-564.
21. Shiota N, Shimoura K, Okunishi H, (2006) Pathophysiological role of mast cells in collagen-induced arthritis: study with a cysteinyl leukotriene receptor antagonist, montelukast. Eur J Pharmacol 548: 158-166.
22. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, et al. (2008) Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 31: 143-178.
23. Parhamifar L, Sime W, Yudina Y, Vilhardt F, Morgelin M, et al. (2010) Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells. PLoS One 5: e14439.
24. Ohd JF, Wikstrom K, Sjolander A, (2000) Leukotrienes induce cell-survival signaling in intestinal epithelial cells. Gastroenterology 119: 1007-1018.
25. Magnusson C, Mezhybovska M, Lorinc E, Fernebro E, Nilbert M, et al. (2010) Low expression of CysLT1R and high expression of CysLT2R mediate good prognosis in colorectal cancer. Eur J Cancer 46: 826-835.
26. Paruchuri S, Sjolander A, (2003) Leukotriene D4 mediates survival and proliferation via separate but parallel pathways in the human intestinal epithelial cell line Int 407. J Biol Chem 278: 45577-45585.
27. Paruchuri S, Broom O, Dib K, Sjolander A, (2005) The pro-inflammatory mediator leukotriene D4 induces phosphatidylinositol 3-kinase and Rac-dependent migration of intestinal epithelial cells. J Biol Chem 280: 13538-13544.
28. Magnusson C, Ehrnstrom R, Olsen J, Sjolander A, (2007) An increased expression of cysteinyl leukotriene 2 receptor in colorectal adenocarcinomas correlates with high differentiation. Cancer Res 67: 9190-9198.
29. Feldman JPGR, Mark S, Schwartz J, (2009) A matematical model for tumor volume evaluation using two-dimensions. J Appl Quant Methods 4: 455-462.
30. Nobili E, Salvado MD, Folkersen L, Castiglioni L, Kastrup J, et al. (2012) Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS One 7: e41786.
31. Genovese T, Rossi A, Mazzon E, Di Paola R, Muia C, et al. (2008) Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol 153: 568-582.
32. Bonville CA, Rosenberg HF, Domachowske JB, (2006) Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis. Antiviral Res 69: 53-59.
33. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, et al. (2004) Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 96: 946-956.
34. Matsuyama M, Hayama T, Funao K, Kawahito Y, Sano H, et al. (2007) Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Oncol Rep 18: 99-104.
35. Truong H, Danen EH, (2009) Integrin switching modulates adhesion dynamics and cell migration. Cell Adh Migr 3: 179-181.
36. Matsuyama M, Funao K, Hayama T, Tanaka T, Kawahito Y, et al. (2009) Relationship between cysteinyl-leukotriene-1 receptor and human transitional cell carcinoma in bladder. Urology 73: 916-921.
37. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, et al. (2008) Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J 22: 3525-3536.
38. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, et al. (2004) Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors. Neurosci Lett 363: 247-251.
39. Magnusson C, Liu J, Ehrnstrom R, Manjer J, Jirstrom K, et al. (2011) Cysteinyl leukotriene receptor expression pattern affects migration of breast cancer cells and survival of breast cancer patients. Int J Cancer 129: 9-22.
40. Aharony D, Falcone RC, Yee YK, Hesp B, Giles RE, et al. (1988) Biochemical and pharmacological characterization of the binding of the selective peptide-leukotriene antagonist, 3H-ICI 198,615, to leukotriene D4 receptors in guinea-pig lung membranes. Ann N Y Acad Sci 524: 162-180.
41. Guay D, Gauthier JY, Dufresne C, Jones TR, McAuliffe M, et al. (1998) A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair. Bioorg Med Chem Lett 8: 453-458.
42. Maekawa A, Austen KF, Kanaoka Y, (2002) Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses. J Biol Chem 277: 20820-20824.
43. Lee KS, Kim SR, Park HS, Jin GY, Lee YC, (2004) Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression. J Allergy Clin Immunol 114: 1093-1099.
44. Nozaki M, Yoshikawa M, Ishitani K, Kobayashi H, Houkin K, et al. (2010) Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. Keio J Med 59: 10-18.
45. Yuan YM, Fang SH, Qian XD, Liu LY, Xu LH, et al. (2009) Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway. J Pharmacol Sci 109: 285-292.
46. Matsuyama M, Yoshimura R, (2010) Cysteinyl-leukotriene1 receptor is a potent target for the prevention and treatment of human urological cancer. Mol Med Report 3: 245-251.
47. Paruchuri S, Mezhybovska M, Juhas M, Sjolander A, (2006) Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells. Oncogene 25: 6660-6665.
48. Cianchi F, Cortesini C, Magnelli L, Fanti E, Papucci L, et al. (2006) Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol Cancer Ther 5: 2716-2726.
49. Peters-Golden M, Henderson WR, (2007) Mechanisms of disease: Leukotrienes. New England Journal of Medicine 357: 1841-1854.
50. Ye YN, Wu WK, Shin VY, Bruce IC, Wong BC, et al. (2005) Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke. Carcinogenesis 26: 827-834.
51. Arjona AA, Alvarez E (2006) Tumor site implantation and animal model selection in oncology. In: Teicher BA, editor. Cancer drug resistance. Springer. 151-160.